Key Drivers
- Cash Cushion
- No Revenue
- Deep Cash Burn
AIAI Summary
PHVS is no longer a survival trade—its May financing extends runway into 2028 and removes near-term balance-sheet stress, but the investment case now depends almost entirely on timely CHAPTER-3 results and NDA execution, so upside is tied to clinical/regulatory delivery rather than cash alone.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •No Revenue
- •Deep Cash Burn
PHVS has a strong cash-rich balance sheet and low leverage, but no revenue, persistent losses, and heavy cash burn make its near-term resilience dependent on continued external financing.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Support holding
- •Momentum cooled
PHVS has maintained a constructive last month uptrend, but the recent pullback from $32.94 to around $30.40 means it needs to hold $30.00 to keep momentum intact.
Sharp run-up to $32.94 was followed by a quick pullback to $30.40, signaling short-term volatility
Sentiment & News
Key News Insights:
- •HAE progress
- •Cash runway
- •Dilution risk
Pharvaris advanced key HAE pipeline milestones and extended its cash runway with a $132.3 million equity raise, while insider sales and dilution may keep near-term sentiment mixed.
The update is supportive for long-term execution and funding, but the stock may face near-term pressure from financing-related dilution and insider selling
Similar Companies in Healthcare
Other companies in the same sector with AI ratings